Compare iShares MSCI Canada (TSX) (EWC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Novartis AG — how do they compare? iShares MSCI Canada (TSX) trades at $61.53, while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while iShares MSCI Canada (TSX) pays none, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| EWC | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.50 | $168.62 |
52-Week Low | $47.00 | $118.55 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC, the iShares MSCI Canada ETF, trades at $61.30, up 0.99% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The fund faces headwinds from renewed U.S.-Canada trade tensions, including 50% tariffs announced in July 2026, though bullish analyst views highlight resilience due to energy and potash exclusions. Key financial ratios are unavailable in the provided data.
Outlook is mixed: technical strength supports near-term gains, but trade policy risks and overbought conditions warrant caution. Investment appeal hinges on Canada's resource-heavy economy navigating tariffs, with diversification benefits for U.S. investors. Risks include escalated trade war impacts on Canadian exports and market volatility.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
